Mesoblast climbs after inking an exclusive global licence from Mayo Clinic
Make us a preferred source
Make us a preferred source on Google
The news: Shares in biotech company Mesoblast rallied in afternoon trade after the company secured an exclusive global licence for an antigen receptor (CAR) technology platform developed at Mayo Clinic.
Shares had risen 8.46% to $2.18 at 12:56pm AEST.
The context: The CAR platform will be used to further boost the effectiveness of Mesoblast’s products by enhancing the targeting of the inherent properties of immunomodulation and tissue regeneration.
As part of the exclusive license, Mayo Clinic will provide support toward further advancing the technology and resulting products.
The source: ASX
